Leadership

Julia Gardner

Founder

Ray Hwang

CTO

Paul Kania

Paul Kania

CFO

Tyler Chen

Tech Operations Lead

Our Advisory Board

The ERMA team and its advisory board have the right skill set and experience to turn this into a successful story

Israel Aker

Senior Manager, Medical Writing & Promotional Review at the PPD™ clinical research business of Thermo Fisher Scientific

Registered Clinical Pharmacist with 20+ years across clinical and industry settings with experience in Pharmacy & Therapeutics, drug safety and pharmacovigilance, medical affairs, and medical writing. Currently serving as Senior Manager, Medical Writing & Promotional Review at Thermo Fisher Scientific.

Ilze Kurins Antons

Founder & Principal
Kurins Consulting, LLC
 

Over three decades of Regulatory Affairs experience in a variety of Pharmaceutical and Biotech companies. Now providing consulting services for advertising and promotion for the pharmaceutical industry.

Christine Hendrick

Director, Commercial Services,
Acadia Pharmaceuticals, Inc.
 

Former lead of Marketing Operations
at Zogenix, Recordati Rare Diseases,
and Lundbeck.

Jaimie Melendez

Jaime Melendez

Strategic Operations, Research
and Product Development, CSL

Former Director, Emerging Technology Partnership and Innovation at Johnson & Johnson. Additionally, Associate Director, Technology Partnership and Business Development at Merck.

Brandon Schlette

Associate Director of Commercial Operations, Recordati Rare Diseases

Associate Director of Commercial Operations at Recordati Rare Diseases of North America with nearly a decade of experience in the pharmaceutical industry. Specializing in workflow-based software, commercial operations initiatives, with a proven track record of managing complex projects and enhancing operational efficiency. Highly proficient in navigating regulatory environments and optimizing marketing operations, evidenced by successful leadership in corporate & marketing processes.

Arvind Sreedharan

Arvind Sreedharan

Sr. VP, Business Operations,
Neurogene Inc.

Three decades of commercial experience. Former VP, of U.S. Commercial Operations for AveXis, the company that developed Zolgensma®, an FDA-approved treatment for spinal muscular atrophy; acquired by Novartis for $8.7 billion.